FUCI CLEAR 1%

  • Therapeutic Category
    • OPHTHALMOLOGICAL DRUGS
    • ANTI-INFECTIVE AGENTS
  • Pharmaceutical Form : Eye Ointments
  • Composition : Fusidic acid 10 mg/ 1 g
  • Active Substance : Fusidic acid

PROPERTIES:

FUCI CLEAR 1% is active against Staphylococci, Streptococci, Neisseria, Haemophilus, Moraxella and Corynebacteria.

The sustained –release formulation of FUCI CLEAR 1% ensures a prolonged contact with the conjunctival sac. A twice-daily application provides sufficient concentrations in all relevant tissues of the eye.

FUCI CLEAR 1% penetrates well into the aqueous humour

INDICATIONS:

Bacteria eye infections caused by susceptible organisms in conjunctivitis, blepharitis, sty, keratitis, dacryocystitis and in connection with removal of foreign bodies

CONTRA-INDICATIONS:

Hypersensitivity to any component.

SIDE EFFECTS:

The most frequently reported adverse drug reactions are various application site reactions such as transient stinging and burning sensation or transient blurring of vision. Urticaria, rash and allergic reactions have been reported.

PRECAUTIONS:

Contact lenses should not be worn when FUCI CLEAR 1% is being used

Discard 30 days after opening.

Bacterial resistance has been reported to occur with the use of fusidic acid. As with all antibiotics, extended or recurrent use may increase the risk of developing antibiotic resistance.

Pregnancy

Limited clinical data on exposed pregnancies is available. This data and animal studies and many years of clinical experience with systemic and topical fusidic acid suggest that fusidic acid is devoid of teratogenic effect. Consequently any risk to the foetus is unlikely using the very low doses of fusidic acid applied topically in FUCI CLEAR can be administered during pregnancy if considered necessary.

Lactation

No effects on the suckling child are anticipated since the systemic exposure of the breast-feeding woman to fusidic acid is negligible. FUCI CLEAR eye gel can be used during breast-feeding.

DOSAGE:

One drop to be instilled into the eye twice daily. Treatment should be continued for at least two days after the eye appears normal

STORAGE:

Don’t store above 25˚ C

PACKING:

Tube containing 5 g